{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:19:01Z","timestamp":1780352341023,"version":"3.54.1"},"reference-count":35,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>We aimed to evaluate whether adding a sustained-release (SR) formula of mosapride to proton-pump inhibitors (PPIs) would be more effective in controlling symptoms than PPI alone in patients with gastroesophageal reflux disease (GERD). Sixty patients with heartburn and\/or regurgitation were randomly assigned to two groups: mosapride SR 15 mg combined with esomeprazole 20 mg once daily (ME group) and esomeprazole 20 mg once daily alone (E group). The primary endpoint was the complete-resolution rate of GERD symptoms after eight-week medication, and the secondary endpoints were the complete-resolution rate of GERD symptoms after four-week medication, symptom-improvement rates \u2265 50% after four- and eight-week medication, and change in reflux-disease-questionnaire (RDQ) and GERD-health-related quality-of-life (GERD-HRQL) scores from baseline at four- and eight-week medication. No significant differences in complete-symptom-resolution rates at eight weeks and four weeks or in the changes in RDQ and GERD-HRQL scores from baseline at four- and eight-week medication were observed between the ME and E groups. The symptom-improvement rate of \u226550% after four and eight weeks was comparable between both groups. Adding mosapride SR to esomeprazole in patients with GERD provides no additional benefits in controlling GERD symptoms.<\/jats:p>","DOI":"10.3390\/jcm11071965","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T21:22:39Z","timestamp":1648848159000},"page":"1965","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Randomized Controlled Trial Comparing the Efficacy of Sustained-Release Formula of Mosapride-Plus-Esomeprazole Combination Therapy to Esomeprazole Monotherapy in Patients with Gastroesophageal Reflux Disease"],"prefix":"10.3390","volume":"11","author":[{"given":"Hye Kyung","family":"Jeon","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Pusan National University College of Medicine, Busan 49241, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9721-5734","authenticated-orcid":false,"given":"Gwang Ha","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pusan National University College of Medicine, Busan 49241, Korea"},{"name":"Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pusan National University College of Medicine, Busan 49241, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Chan","family":"Joo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pusan National University College of Medicine, Busan 49241, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bong Eun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pusan National University College of Medicine, Busan 49241, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","article-title":"The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus","volume":"101","author":"Vakil","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1038\/s41598-020-62795-1","article-title":"Global prevalence and risk factors of gastro-oesophageal reflux disease (GORD): Systematic review with meta-analysis","volume":"10","author":"Nirwan","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/gutjnl-2012-304269","article-title":"Update on the epidemiology of gastro-oesophageal reflux disease: A systematic review","volume":"63","author":"Sweet","year":"2014","journal-title":"Gut"},{"key":"ref_4","first-page":"390","article-title":"Gastro-esophageal reflux disease: Key messages for clinicians","volume":"67","author":"Saracco","year":"2021","journal-title":"Minerva Gastroenterol. Dietol."},{"key":"ref_5","first-page":"S33","article-title":"Proton pump inhibitor failure\u2014What are the therapeutic options?","volume":"104","author":"Fass","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/S0140-6736(06)68932-0","article-title":"Gastro-oesophageal reflux disease","volume":"367","author":"Moayyedi","year":"2006","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1440-1746.2007.05249.x","article-title":"Asia-Pacific consensus on the management of gastroesophageal reflux disease: Update","volume":"23","author":"Fock","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1111\/j.1572-0241.2000.03254.x","article-title":"Oral pantoprazole for erosive esophagitis: A placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group","volume":"95","author":"Richter","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"ref_9","first-page":"1749","article-title":"Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group","volume":"91","author":"Castell","year":"1996","journal-title":"Am. J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2036.2005.02531.x","article-title":"Systematic review: Proton-pump inhibitor failure in gastro-oesophageal reflux disease\u2014Where next?","volume":"22","author":"Fass","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.3748\/wjg.v20.i9.2412","article-title":"Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: A meta-analysis","volume":"20","author":"Ren","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_12","first-page":"220","article-title":"Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: Implications for proarrhythmic potential?","volume":"282","author":"Carlsson","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2036.1998.00268.x","article-title":"The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease","volume":"12","author":"Ruth","year":"1998","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00535-009-0173-0","article-title":"The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying","volume":"45","author":"Futagami","year":"2010","journal-title":"J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5056\/jnm20161","article-title":"A Systematic review and meta-analysis of randomized control trials: Combination treatment with proton pump inhibitor plus prokinetic for gastroesophageal reflux disease","volume":"27","author":"Jung","year":"2021","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.5056\/jnm16100","article-title":"A Double-blind, randomized, multicenter clinical trial investigating the efficacy and safety of esomeprazole single therapy versus mosapride and esomeprazole combined therapy in patients with esophageal reflux disease","volume":"23","author":"Lee","year":"2017","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1442-2050.2004.00424.x","article-title":"Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: A randomized trial","volume":"17","author":"Madan","year":"2004","journal-title":"Dis. Esophagus"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Nishizawa, T., Mori, K., Yoshida, S., Ebinuma, H., Toyoshima, O., and Suzuki, H. (2020). additional mosapride to proton pump inhibitor for gastroesophageal reflux disease: A meta-analysis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092705"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5056\/jnm20061","article-title":"Efficacy and Safety of DWJ1252 compared with gasmotin in the treatment of functional dyspepsia: A multicenter, randomized, double-blind, active-controlled study","volume":"27","author":"Park","year":"2021","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1572-0241.2001.03451.x","article-title":"Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease","volume":"96","author":"Shaw","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1442-2050.2007.00658.x","article-title":"The development of the GERD-HRQL symptom severity instrument","volume":"20","author":"Velanovich","year":"2007","journal-title":"Dis. Esophagus"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/gut.45.2.172","article-title":"Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification","volume":"45","author":"Lundell","year":"1999","journal-title":"Gut"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/00365529609094509","article-title":"Gastritis in the Japanese stomach","volume":"214","author":"Kimura","year":"1996","journal-title":"Scand. J. Gastroenterol. Suppl."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00228-007-0287-3","article-title":"Tegaserod for dyspepsia and reflux symptoms in patients with chronic constipation: An exploratory open-label study","volume":"63","author":"Zeng","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"15154","DOI":"10.1038\/s41598-020-72082-8","article-title":"Treatment of non-erosive reflux disease and dynamics of the esophageal microbiome: A prospective multicenter study","volume":"10","author":"Park","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/CEG.S214677","article-title":"Efficacy of the four weeks treatment of omeprazole plus mosapride combination therapy compared with that of omeprazole monotherapy in patients with proton pump inhibitor-refractory gastroesophageal reflux disease: A randomized controlled trial","volume":"12","author":"Sirinawasatien","year":"2019","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.5056\/jnm.2013.19.4.495","article-title":"effects of the addition of mosapride to gastroesophageal reflux disease patients on proton pump inhibitor: A prospective randomized, double-blind study","volume":"19","author":"Lim","year":"2013","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/1751-2980.12167","article-title":"Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease","volume":"15","author":"Yamaji","year":"2014","journal-title":"J. Dig. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2036.2010.04517.x","article-title":"Randomised clinical trial: Efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease\u2014A double-blind, placebo-controlled study","volume":"33","author":"Miwa","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"9111","DOI":"10.3748\/wjg.v19.i47.9111","article-title":"Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease: A systematic review","volume":"19","author":"Liu","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1542-3565(04)00288-5","article-title":"Effectiveness of proton pump inhibitors in nonerosive reflux disease","volume":"2","author":"Dean","year":"2004","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.3748\/wjg.14.3123","article-title":"Strategy for treatment of nonerosive reflux disease in Asia","volume":"14","author":"Hiyama","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2125.2010.03696.x","article-title":"Mosapride as an adjunct to lansoprazole for symptom relief of reflux oesophagitis","volume":"70","author":"Hsu","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2165\/00003495-200868070-00007","article-title":"Mosapride in gastrointestinal disorders","volume":"68","author":"Curran","year":"2008","journal-title":"Drugs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/00365520510011579","article-title":"High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: A Kalixanda study report","volume":"40","author":"Ronkainen","year":"2005","journal-title":"Scand. J. Gastroenterol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/7\/1965\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:48:15Z","timestamp":1760136495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/7\/1965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["jcm11071965"],"URL":"https:\/\/doi.org\/10.3390\/jcm11071965","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]}}}